Grupos de investigación

  1. Portada
  2. Publicaciones
  3. Publicaciones 1995-1997

Publicaciones 1995-1997

Publicaciones anteriores

  1. “Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages”. Pozo D, Delgado M, Martínez C, Gomariz RP, Guerrero JM, Calvo JR. Biochim Biophys Acta. 1997 Dec 12;1359(3):250-62.
  2. “Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen”. Pozo D, Delgado M, Fernandez-Santos JM, Calvo JR, Gomariz RP, Martin-Lacave I, Ortiz GG, Guerrero JM. FASEB J. 1997 May;11(6):466-73. PDF
  3. “Ontogenic development of the adenylyl cyclase enzyme and the alpha s, alpha i1 and alpha i2 G-protein regulatory subunits from rat prostate”. Juarranz MG, Carrero I, Busto R, Carmena MJ, Prieto JC, Guijarro LG. Cell Signal. 1997 Sep;9(6):451-6.
  4. “Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus”. Rodríguez-Sánchez MN, Puebla L, López-Sañudo S, Rodríguez-Martín E, Martín-Espinosa A, Rodríguez-Pena MS, Juarranz MG, Arilla E. J Neurosci Res. 1997 May 1;48(3):238-48.
  5. “Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP, and carbachol: role in prostatic proliferation”. Guijarro LG, Juarranz MG, Marinero MJ, Pajuelo L, Carmena MJ, Prieto JC. Ann N Y Acad Sci. 1996 Dec 26;805:723-8.
  6. “Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility”. Garrido E, Delgado M, Martínez C, Gomariz RP, De la Fuente M. Neuropeptides. 1996 Dec;30(6):583-95.
  7. “Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes”. Delgado M, Martínez C, Johnson MC, Gomariz RP, Ganea D. J Neuroimmunol. 1996 Aug;68(1-2):27-38.
  8. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis”. Delgado M, Garrido E, Martínez C, Leceta J, Gomariz RP. Blood. 1996 Jun 15;87(12):5152-61. PDF
  9. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes”. Martínez C, Delgado M, Gomariz RP, Ganea D. J Immunol. 1996 Jun 1;156(11):4128-36.
  10. “Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages”. Delgado M, Pozo D, Martínez C, Garrido E, Leceta J, Calvo JR, Gomariz RP. Regul Pept. 1996 Apr 23;62(2-3):161-6.
  11. “Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA”. Johnson MC1, McCormack RJ, Delgado M, Martínez C, Ganea D. J Neuroimmunol. 1996 Aug;68(1-2):109-19.
  12.  “Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions”. Delgado M, Garrido E, de la Fuente M, Gomariz RP. Peptides. 1996;17(7):1097-105.
  13. “Differential VIP and VIP1 receptor gene expression in rat thymocyte subsets”. Delgado M, Martínez C, Leceta J, Garrido E, Gomariz RP. Peptides. 1996;17(5):803-7.
  14. “VIP modulation of immune cell functions”. De la Fuente M, Delgado M, Gomariz RP. Adv Neuroimmunol. 1996;6(1):75-91. 
  15. “Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system”. Leceta J, Martínez C, Delgado M, Garrido E, Gomariz RP. Adv Neuroimmunol. 1996;6(1):29-36. 
  16. “Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP”. Delgado M, De la Fuente M, Martínez C, Gomariz RP. J Neuroimmunol. 1995 Nov;62(2):137-46.
  17. “Receptors for pituitary adenylate cyclase-activating peptide in human liver”. Guijarro LG, Rodríguez-Henche N, García-López E, Noguerales F, Dapena MA, Juarranz MG, Prieto JC. J Clin Endocrinol Metab. 1995 Aug;80(8):2451-7.